A man walks past the New York Stock Exchange after trading hours in New York in this August 17, 2009 file photo. U.S. drug regulators may have a hard time stopping millions of overweight Americans from taking a new obesity drug that many are likely to view as a miracle pill for slimming waistlines, despite its safety risks and potentially short-term effects. To match Analysis HEALTH-OBESITY/FDA   REUTERS/Lucas Jackson/Files (UNITED STATES - Tags: DRUGS SOCIETY HEALTH)